Featured Research

from universities, journals, and other organizations

Hepatitis C Treatment Less Effective in Urban Minority Patients

Date:
March 25, 2010
Source:
Wiley - Blackwell
Summary:
A recent study confirms that the standard hepatitis C (HCV) therapy, pegylated interferon and ribavirin, is significantly less effective in urban minority patients treated in an ordinary clinical practice setting compared with results produced during clinical trials.

A recent study confirms that the standard hepatitis C (HCV) therapy, pegylated interferon and ribavirin, is significantly less effective in urban minority patients treated in an ordinary clinical practice setting compared with results produced during clinical trials. Results of this study appear in the April issue of Hepatology.

Related Articles


According to the CDC's Office of Minority Health & Health Disparities (OMHD), minorities experience a disproportionate burden of preventable disease, death, and disability compared with non-minorities. Groups currently experiencing poorer health status are expected to grow as a proportion of the total U.S. population. African Americans have higher rates of HCV and hepatitis B (HBV) infection than whites or Hispanics, while hepatitis A (HAV) rates are higher among Hispanics than among non-Hispanics. Current information about the biologic and genetic characteristics of minority populations does not explain the health disparities experienced by these groups compared with the white, non-Hispanic population in the U.S. These disparities are believed to be the result of the complex interaction among genetic variations, environmental factors, and specific health behaviors.

A study conducted at the Albert Einstein College of Medicine supports the disparity in drug efficacy among various minority populations. Researchers analyzed combination pegylated interferon and ribavirin, which has proved an effective treatment regimen for HCV in clinical trials, but doesn't yield the same success rates in daily clinical practice, particularly with minority patients. Study leader Dr. John F. Reinus explains, "Industry-sponsored trials are conducted with the advantage of extraordinary resources to ensure that all aspects of therapy with a study drug are accurately controlled, observed and documented."

Researchers noted that because Hispanics and African-Americans are underrepresented in clinical trials, the results do not necessarily reflect how trial drugs will affect these patients. In fact, studies have shown that African-American and Hispanic patients infected with HCV are less likely to have a sustained viral response (SVR) to treatment compared to non-Hispanic whites. Nevertheless, efficacy data from randomized controlled therapeutic trials are commonly used to make important treatment decisions. "Practitioners need to know not only the efficacy of combination therapy as demonstrated in phase-III registration trials, but also its effectiveness: the outcome of treatment in patients like their own receiving ordinary clinical care," Dr. Reinus says.

Patients were seen in the private Faculty Practice of the Albert Einstein College of Medicine or the attending-supervised Liver Clinic at Montefiore Medical Center, Bronx, New York. Patients in both settings had the same liberal access to treating physicians and their therapy was similarly supported by ancillary services. These resources were felt to equal or exceed in quality and availability those accessible to non-hospital-based private-practice patients. In addition, the same aggressive approach to side-effect management was used in both practice settings, and dose reductions were avoided unless drug side effects could be managed in no other way.

A total of 255 HCV patients were evaluated. The majority of study patients were Hispanic (149), followed by African-American (52), other (31), and Caucasian (23). One-hundred thirty-one patients (51%) completed treatment and SVR was achieved in 54 patients, of whom 63% were Hispanic, 8% were African-American, and 17% were Caucasian. By contrast, multinational phase-III randomized controlled trials of HCV therapy with combination pegylated interferon and ribavirin, intention-to-treat analysis has consistently shown SVR rates of 54 to 63%.

"Published reports suggest that therapy is less effective in urban HCV patients than in persons enrolled in registration trials, which include mostly patients of western-European ancestry, Dr. Reinus says. "This hypothesis is confirmed by our data: the overall SVR rate in our patients was one-third to less than one-half that predicted on the basis of registration trials. This discrepancy does not appear to be accounted for by other factors, including patient demographics and features of infection. We conclude that new strategies are needed to care for such patients.


Story Source:

The above story is based on materials provided by Wiley - Blackwell. Note: Materials may be edited for content and length.


Journal Reference:

  1. Feuerstadt et al. Effectiveness of hepatitis C treatment with pegylated interferon and ribavirin in urban minority patients. Hepatology, 2010; DOI: 10.1002/hep.23429

Cite This Page:

Wiley - Blackwell. "Hepatitis C Treatment Less Effective in Urban Minority Patients." ScienceDaily. ScienceDaily, 25 March 2010. <www.sciencedaily.com/releases/2010/03/100325095905.htm>.
Wiley - Blackwell. (2010, March 25). Hepatitis C Treatment Less Effective in Urban Minority Patients. ScienceDaily. Retrieved December 19, 2014 from www.sciencedaily.com/releases/2010/03/100325095905.htm
Wiley - Blackwell. "Hepatitis C Treatment Less Effective in Urban Minority Patients." ScienceDaily. www.sciencedaily.com/releases/2010/03/100325095905.htm (accessed December 19, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, December 19, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

The Best Tips to Curb Holiday Carbs

The Best Tips to Curb Holiday Carbs

Buzz60 (Dec. 19, 2014) It's hard to resist those delicious but fattening carbs we all crave during the winter months, but there are some ways to stay satisfied without consuming the extra calories. Vanessa Freeman (@VanessaFreeTV) has the details. Video provided by Buzz60
Powered by NewsLook.com
Sierra Leone Bikers Spread the Message to Fight Ebola

Sierra Leone Bikers Spread the Message to Fight Ebola

AFP (Dec. 19, 2014) More than 100 motorcyclists hit the road to spread awareness messages about Ebola. Nearly 7,000 people have now died from the virus, almost all of them in west Africa, according to the World Health Organization. Video provided by AFP
Powered by NewsLook.com
Researchers Test Colombian Village With High Alzheimer's Rates

Researchers Test Colombian Village With High Alzheimer's Rates

AFP (Dec. 19, 2014) In Yarumal, a village in N. Colombia, Alzheimer's has ravaged a disproportionately large number of families. A genetic "curse" that may pave the way for research on how to treat the disease that claims a new victim every four seconds. Duration: 02:42 Video provided by AFP
Powered by NewsLook.com
Kids Die While Under Protective Services

Kids Die While Under Protective Services

AP (Dec. 18, 2014) As part of a six-month investigation of child maltreatment deaths, the AP found that hundreds of deaths from horrific abuse and neglect could have been prevented. AP's Haven Daley reports. (Dec. 18) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins